Article: Efficient CAR-T Development Workflows with Advanced Screening Solutions

Overview

The development of Chimeric Antigen Receptor (CAR) constructs for CAR-T cell therapy faces significant challenges, particularly in ensuring specificity for target antigens. These challenges can lead to issues such as tumor resistance, on-target off-tumor effects, and toxicities associated with CAR-T cell activation.

Advanced optical biosensing technology plays a crucial role in addressing some of the challenges in CAR construct development. Biolayer Interferometry (BLI) offers real-time analysis of biomolecular interactions without the need for fluorescent labeling. This label-free approach is particularly advantageous for studying unmodified biomolecules, providing insights into binding kinetics, affinity, and interaction concentrations in various biological contexts.

BLI utilizes optical interference to detect changes in the biological layer of a biosensor tip, enabling precise, real-time monitoring of molecular interactions. This technology is ideally suited for high-throughput screening due to its compatibility with diverse sample types, minimal sample preparation requirements, and low sample volume needs. The non-destructive, fluidic-free assay format of BLI allows for direct analysis in 96- or 384-well plates, significantly enhancing throughput and efficiency in CAR-T development workflows.

This article compiles various studies that highlight the Octet^® BLI system as a valuable tool in the creation and testing of CAR constructs for both research and clinical applications.

• Document type: Article
• Page count: 8
• Read time: 12 minutes

Complete the Form to Access the Article